Iceland: Alvotech to merge with Oaktree SPAC ahead of IPO on Nasdaq


Biosimilar medicine manufacturer, Alvotech, is planning to merge with Oaktree Capital SPAC, Oaktree Acquisition Corp, with the intention of going public with an IPO on Nasdaq. The deal values the combined company at US$2.25bn and is expected to deliver more than US$450m to Alvotech, which includes cash proceeds of approximately US$250m from Oaktree Acquisition Corp’s…

You must be a HMI Subscriber to view this content.

Subscribe Now »